Clinical Trial Update: IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rmhTNF-NC in combination with tislelizumab and palliative radiotherapy for digestive system neoplasms with malignant ascites a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neoplasms

Drugs mentioned

• Tislelizumab (tislelizumab)
• rmhTNF-NC (rmhTNF-NC)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Digestive System Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING